Pharmacological inhibition of ADAM17 led to an amelioration of the pathology, thus indicating that TIMP-3 links the interplay between reduced insulin action and aberrant ADAM17 activity in diabetes and vascular inflammation [87]. The gene discussed is ADAM17; the disease is diabetes mellitus.